IBP · Installed Building Products, Inc.

The price represents the weighted average sale price for multiple transactions reported on this line. The prices of the transactions reported on this line range from $204.9900 to $205.9500. The Reporting Person undertakes to provide, upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

The price represents the weighted average sale price for multiple transactions reported on this line. The prices of the transactions reported on this line range from $198.4350 to $198.8410. The Reporting Person undertakes to provide, upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

The price represents the weighted average sale price for multiple transactions reported on this line. The prices of the transactions reported on this line range from $206.5250 to $207.0400. The Reporting Person undertakes to provide, upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

The price represents the weighted average sale price for multiple transactions reported on this line. The prices of the transactions reported on this line range from $197.3791 to $198.0100. The Reporting Person undertakes to provide, upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

The price represents the weighted average sale price for multiple transactions reported on this line. The prices of the transactions reported on this line range from $202.4100 to $203.2123. The Reporting Person undertakes to provide, upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

The price represents the weighted average sale price for multiple transactions reported on this line. The prices of the transactions reported on this line range from $201.3100 to $202.2750. The Reporting Person undertakes to provide, upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

The price represents the weighted average sale price for multiple transactions reported on this line. The prices of the transactions reported on this line range from $195.2738 to $196.2670. The Reporting Person undertakes to provide, upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

The price represents the weighted average sale price for multiple transactions reported on this line. The prices of the transactions reported on this line range from $196.3250 to $197.3100. The Reporting Person undertakes to provide, upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

The price represents the weighted average sale price for multiple transactions reported on this line. The prices of the transactions reported on this line range from $203.9100 to $204.7300. The Reporting Person undertakes to provide, upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

The restricted stock shall vest on the earlier to occur of (i) the one year anniversary of the grant date, (ii) immediately prior to the first annual meeting of the Company's stockholders occurring after the grant date or (iii) the director's death, subject in the cases of (i) and (ii) to such director's continued service as a member of the board of directors from the grant date through the vesting date. The date of grant of the restricted stock was May 19, 2026.

The restricted stock shall vest on the earlier to occur of (i) the one year anniversary of the grant date, (ii) immediately prior to the first annual meeting of the Company's stockholders occurring after the grant date or (iii) the director's death, subject in the cases of (i) and (ii) to such director's continued service as a member of the board of directors from the grant date through the vesting date. The date of grant of the restricted stock was May 19, 2026.

The restricted stock shall vest on the earlier to occur of (i) the one year anniversary of the grant date, (ii) immediately prior to the first annual meeting of the Company's stockholders occurring after the grant date or (iii) the director's death, subject in the cases of (i) and (ii) to such director's continued service as a member of the board of directors from the grant date through the vesting date. The date of grant of the restricted stock was May 19, 2026.

The restricted stock shall vest on the earlier to occur of (i) the one year anniversary of the grant date, (ii) immediately prior to the first annual meeting of the Company's stockholders occurring after the grant date or (iii) the director's death, subject in the cases of (i) and (ii) to such director's continued service as a member of the board of directors from the grant date through the vesting date. The date of grant of the restricted stock was May 19, 2026.

The restricted stock shall vest on the earlier to occur of (i) the one year anniversary of the grant date, (ii) immediately prior to the first annual meeting of the Company's stockholders occurring after the grant date or (iii) the director's death, subject in the cases of (i) and (ii) to such director's continued service as a member of the board of directors from the grant date through the vesting date. The date of grant of the restricted stock was May 19, 2026.

The restricted stock shall vest on the earlier to occur of (i) the one year anniversary of the grant date, (ii) immediately prior to the first annual meeting of the Company's stockholders occurring after the grant date or (iii) the director's death, subject in the cases of (i) and (ii) to such director's continued service as a member of the board of directors from the grant date through the vesting date. The date of grant of the restricted stock was May 19, 2026.

The restricted stock shall vest on the earlier to occur of (i) the one year anniversary of the grant date, (ii) immediately prior to the first annual meeting of the Company's stockholders occurring after the grant date or (iii) the director's death, subject in the cases of (i) and (ii) to such director's continued service as a member of the board of directors from the grant date through the vesting date. The date of grant of the restricted stock was May 19, 2026.

Gift to a charitable organization.

The price represents the weighted average sale price for multiple transactions reported on this line. The prices of the transactions reported on this line range from $210.1400 to $211.0458. The Reporting Person undertakes to provide, upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

The price represents the weighted average sale price for multiple transactions reported on this line. The prices of the transactions reported on this line range from $215.8050 to $216.7450. The Reporting Person undertakes to provide, upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

The price represents the weighted average sale price for multiple transactions reported on this line. The prices of the transactions reported on this line range from $205.6250 to $206.5750. The Reporting Person undertakes to provide, upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

The price represents the weighted average sale price for multiple transactions reported on this line. The prices of the transactions reported on this line range from $213.5600 to $214.3100. The Reporting Person undertakes to provide, upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

The price represents the weighted average sale price for multiple transactions reported on this line. The prices of the transactions reported on this line range from $211.2688 to $212.0960. The Reporting Person undertakes to provide, upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

The price represents the weighted average sale price for multiple transactions reported on this line. The prices of the transactions reported on this line range from $203.5700 to $204.5366. The Reporting Person undertakes to provide, upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

The price represents the weighted average sale price for multiple transactions reported on this line. The prices of the transactions reported on this line range from $214.8000 to $215.2550. The Reporting Person undertakes to provide, upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

The price represents the weighted average sale price for multiple transactions reported on this line. The prices of the transactions reported on this line range from $208.0250 to $208.9850. The Reporting Person undertakes to provide, upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

The price represents the weighted average sale price for multiple transactions reported on this line. The prices of the transactions reported on this line range from $212.4521 to $213.0500. The Reporting Person undertakes to provide, upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

The price represents the weighted average sale price for multiple transactions reported on this line. The prices of the transactions reported on this line range from $209.0400 to $209.8300. The Reporting Person undertakes to provide, upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

The price represents the weighted average sale price for multiple transactions reported on this line. The prices of the transactions reported on this line range from $206.8050 to $207.6850. The Reporting Person undertakes to provide, upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

The price represents the weighted average sale price for multiple transactions reported on this line. The prices of the transactions reported on this line range from $216.8600 to $217.8100. The Reporting Person undertakes to provide, upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

The price represents the weighted average sale price for multiple transactions reported on this line. The prices of the transactions reported on this line range from $204.6200 to $205.6100. The Reporting Person undertakes to provide, upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

Represents shares withheld to satisfy tax withholding obligation on vesting of 3,155 shares of restricted stock pursuant to the 2023 Omnibus Incentive Plan.

Represents shares withheld to satisfy tax withholding obligation on vesting of 1,698 shares of restricted stock pursuant to the 2023 Omnibus Incentive Plan.

Represents shares withheld to satisfy tax withholding obligation on vesting of 26,799 shares of restricted stock pursuant to the 2023 Omnibus Incentive Plan.

Represents shares withheld to satisfy tax withholding obligation on vesting of 2,330 shares of restricted stock pursuant to the 2023 Omnibus Incentive Plan.

Represents shares withheld to satisfy tax withholding obligation on vesting of 8,544 shares of restricted stock pursuant to the 2023 Omnibus Incentive Plan.

Represents shares withheld to satisfy tax withholding obligation on vesting of 7,229 shares of restricted stock pursuant to the 2023 Omnibus Incentive Plan.

Reflects the gift of common stock to a charitable fund.

These shares are held by a trust of which Mr. Miller is the sole trustee and sole beneficiary and exercises sole voting and investment power.

Gift to a charitable organization.

As previously reported, IBS entered into two prepaid variable forward sale contracts on each of September 2023, November 2023 and May 2024 with an unaffiliated third party buyer. In each of the September and November transactions, IBS pledged 450,000 shares, or 225,000 shares per contract and 900,000 shares in the aggregate, and in the May transaction, IBS pledged 250,000 shares, or 125,000 shares per contract (collectively, the "Pledged Shares") of Installed Building Products, Inc. common stock ("Common Stock"). The Pledged Shares secure its obligations under the contracts, and IBS retained dividend and voting rights in the Pledged Shares during the term of the pledge. The contracts obligate IBS to deliver to the buyer, on the applicable settlement date for each component referred to in footnote 10 below, up to one hundred percent (100%) of the number of Pledged Shares for such component or, at IBS' option, an equivalent amount of cash.

On August 12, 2025, IBS and the buyer entered into an amendment to the September 2023 forward sale contract and the May 2024 forward sale contract. On March 3, 2026, IBS and the buyer entered into a second amendment to the September 2023 forward sale contract (the "September Amendment Agreement") and the May 2024 forward sale contract (the "May Amendment Agreement" and collectively the "2026 Amendment Agreements"). The reference price for the 2026 Amendment Agreements was $314.06. The September Amendment Agreement amends certain terms of one of the forward sale contracts entered into in September 2023, covering 225,000 shares of Common Stock, including (i) extending the range of settlement dates for the components from March 9, 2026 through March 13, 2026 to the new settlement dates from May 24, 2027 through June 4, 2027,

(Continued from footnote 6) (ii) amending the Floor Price (as defined below) and the Cap Price (as defined below), and (iii) increasing the number of components from 5 to 9, with appropriate adjustment for the number of shares to be delivered on the respective settlement date for each component. The May Amendment Agreement amends certain terms of one of the forward sale contracts entered into in May 2024, covering 125,000 shares of Common Stock, including (i) extending the range of settlement dates for the components from March 9, 2026 through March 13, 2026 to the new settlement dates from May 24, 2027 through June 4, 2027, (ii) amending the Floor Price (as defined below) and the Cap Price (as defined below), and (iii) increasing the number of components from 5 to 9, with appropriate adjustments for the number of shares to be delivered on the respective settlement date for each component.

(Continued from footnote 7) The number of shares of Common Stock to be delivered to the buyer on the settlement date (or on which to base the amount of cash to be delivered to the buyer on such settlement date) under each Amendment Agreement is to be determined as follows: (a) if the VWAP of the Common Stock on the designated valuation date for the applicable component (each, a "Settlement Price") is less than or equal to $314.06 (the "Floor Price"), IBS will deliver to the buyer all of the Pledged Shares for the applicable component;

(Continued from footnote 8) (b) if such Settlement Price is greater than the Floor Price but less than or equal to $376.872 (the "Cap Price"), IBS will deliver to the buyer the number of shares equal to 100% of the Pledged Shares for the applicable component multiplied by a fraction, the numerator of which is the Floor Price and the denominator of which is such Settlement Price; and (c) if such Settlement Price is greater than the Cap Price, IBS will deliver to the buyer the number of shares equal to 100% of the Pledged Shares for the applicable component multiplied by a fraction, the numerator of which is the Floor Price plus the excess of such Settlement Price over the Cap Price, and the denominator of which is such Settlement Price.

Each component is exercisable on the same date as it expires, and the expiration dates for the components occur from May 24, 2027 through June 4, 2027 under the 2026 Amendment Agreements.

These securities are held directly by IBS. Mr. Edwards disclaims beneficial ownership in the reported securities except to the extent of his pecuniary interest therein.

As previously reported, IBS entered into two prepaid variable forward sale contracts on each of September 2023, November 2023 and May 2024 with an unaffiliated third party buyer. In each of the September and November transactions, IBS pledged 450,000 shares, or 225,000 shares per contract and 900,000 shares in the aggregate, and in the May transaction, IBS pledged 250,000 shares, or 125,000 shares per contract (collectively, the "Pledged Shares") of Installed Building Products, Inc. common stock ("Common Stock"). The Pledged Shares secure its obligations under the contracts, and IBS retained dividend and voting rights in the Pledged Shares during the term of the pledge. The contracts obligate IBS to deliver to the buyer, on the applicable settlement date for each component referred to in footnote 10 below, up to one hundred percent (100%) of the number of Pledged Shares for such component or, at IBS' option, an equivalent amount of cash.

On August 12, 2025, IBS and the buyer entered into an amendment to the September 2023 forward sale contract and the May 2024 forward sale contract. On March 3, 2026, IBS and the buyer entered into a second amendment to the September 2023 forward sale contract (the "September Amendment Agreement") and the May 2024 forward sale contract (the "May Amendment Agreement" and collectively the "2026 Amendment Agreements"). The reference price for the 2026 Amendment Agreements was $314.06. The September Amendment Agreement amends certain terms of one of the forward sale contracts entered into in September 2023, covering 225,000 shares of Common Stock, including (i) extending the range of settlement dates for the components from March 9, 2026 through March 13, 2026 to the new settlement dates from May 24, 2027 through June 4, 2027,

(Continued from footnote 6) (ii) amending the Floor Price (as defined below) and the Cap Price (as defined below), and (iii) increasing the number of components from 5 to 9, with appropriate adjustment for the number of shares to be delivered on the respective settlement date for each component. The May Amendment Agreement amends certain terms of one of the forward sale contracts entered into in May 2024, covering 125,000 shares of Common Stock, including (i) extending the range of settlement dates for the components from March 9, 2026 through March 13, 2026 to the new settlement dates from May 24, 2027 through June 4, 2027, (ii) amending the Floor Price (as defined below) and the Cap Price (as defined below), and (iii) increasing the number of components from 5 to 9, with appropriate adjustments for the number of shares to be delivered on the respective settlement date for each component.

(Continued from footnote 7) The number of shares of Common Stock to be delivered to the buyer on the settlement date (or on which to base the amount of cash to be delivered to the buyer on such settlement date) under each Amendment Agreement is to be determined as follows: (a) if the VWAP of the Common Stock on the designated valuation date for the applicable component (each, a "Settlement Price") is less than or equal to $314.06 (the "Floor Price"), IBS will deliver to the buyer all of the Pledged Shares for the applicable component;

(Continued from footnote 8) (b) if such Settlement Price is greater than the Floor Price but less than or equal to $376.872 (the "Cap Price"), IBS will deliver to the buyer the number of shares equal to 100% of the Pledged Shares for the applicable component multiplied by a fraction, the numerator of which is the Floor Price and the denominator of which is such Settlement Price; and (c) if such Settlement Price is greater than the Cap Price, IBS will deliver to the buyer the number of shares equal to 100% of the Pledged Shares for the applicable component multiplied by a fraction, the numerator of which is the Floor Price plus the excess of such Settlement Price over the Cap Price, and the denominator of which is such Settlement Price.

Each component is exercisable on the same date as it expires, and the expiration dates for the components occur from May 24, 2027 through June 4, 2027 under the 2026 Amendment Agreements.

These securities are held directly by IBS. Mr. Edwards disclaims beneficial ownership in the reported securities except to the extent of his pecuniary interest therein.

As previously reported, IBS entered into two prepaid variable forward sale contracts on each of September 2023, November 2023 and May 2024 with an unaffiliated third party buyer. In each of the September and November transactions, IBS pledged 450,000 shares, or 225,000 shares per contract and 900,000 shares in the aggregate, and in the May transaction, IBS pledged 250,000 shares, or 125,000 shares per contract (collectively, the "Pledged Shares") of Installed Building Products, Inc. common stock ("Common Stock"). The Pledged Shares secure its obligations under the contracts, and IBS retained dividend and voting rights in the Pledged Shares during the term of the pledge. The contracts obligate IBS to deliver to the buyer, on the applicable settlement date for each component referred to in footnote 10 below, up to one hundred percent (100%) of the number of Pledged Shares for such component or, at IBS' option, an equivalent amount of cash.

On August 12, 2025, IBS and the buyer entered into an amendment to the September 2023 forward sale contract and the May 2024 forward sale contract. On March 3, 2026, IBS and the buyer entered into a second amendment to the September 2023 forward sale contract (the "September Amendment Agreement") and the May 2024 forward sale contract (the "May Amendment Agreement" and collectively the "2026 Amendment Agreements"). The reference price for the 2026 Amendment Agreements was $314.06. The September Amendment Agreement amends certain terms of one of the forward sale contracts entered into in September 2023, covering 225,000 shares of Common Stock, including (i) extending the range of settlement dates for the components from March 9, 2026 through March 13, 2026 to the new settlement dates from May 24, 2027 through June 4, 2027,

(Continued from footnote 6) (ii) amending the Floor Price (as defined below) and the Cap Price (as defined below), and (iii) increasing the number of components from 5 to 9, with appropriate adjustment for the number of shares to be delivered on the respective settlement date for each component. The May Amendment Agreement amends certain terms of one of the forward sale contracts entered into in May 2024, covering 125,000 shares of Common Stock, including (i) extending the range of settlement dates for the components from March 9, 2026 through March 13, 2026 to the new settlement dates from May 24, 2027 through June 4, 2027, (ii) amending the Floor Price (as defined below) and the Cap Price (as defined below), and (iii) increasing the number of components from 5 to 9, with appropriate adjustments for the number of shares to be delivered on the respective settlement date for each component.

(Continued from footnote 7) The number of shares of Common Stock to be delivered to the buyer on the settlement date (or on which to base the amount of cash to be delivered to the buyer on such settlement date) under each Amendment Agreement is to be determined as follows: (a) if the VWAP of the Common Stock on the designated valuation date for the applicable component (each, a "Settlement Price") is less than or equal to $314.06 (the "Floor Price"), IBS will deliver to the buyer all of the Pledged Shares for the applicable component;

(Continued from footnote 8) (b) if such Settlement Price is greater than the Floor Price but less than or equal to $376.872 (the "Cap Price"), IBS will deliver to the buyer the number of shares equal to 100% of the Pledged Shares for the applicable component multiplied by a fraction, the numerator of which is the Floor Price and the denominator of which is such Settlement Price; and (c) if such Settlement Price is greater than the Cap Price, IBS will deliver to the buyer the number of shares equal to 100% of the Pledged Shares for the applicable component multiplied by a fraction, the numerator of which is the Floor Price plus the excess of such Settlement Price over the Cap Price, and the denominator of which is such Settlement Price.

Each component is exercisable on the same date as it expires, and the expiration dates for the components occur from May 24, 2027 through June 4, 2027 under the 2026 Amendment Agreements.

These securities are held directly by IBS. Mr. Edwards disclaims beneficial ownership in the reported securities except to the extent of his pecuniary interest therein.

PJAM IBP Holdings, Inc. ("PJAM") sold 400,000 shares of common stock of Installed Building Products, Inc. through a block trade pursuant to Rule 144 under the Securities Act of 1933, as amended.

These securities are held directly by PJAM. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of his or its pecuniary interest therein. IBP Holding Company is the sole shareholder of PJAM.

As previously reported, IBS entered into two prepaid variable forward sale contracts on each of September 2023, November 2023 and May 2024 with an unaffiliated third party buyer. In each of the September and November transactions, IBS pledged 450,000 shares, or 225,000 shares per contract and 900,000 shares in the aggregate, and in the May transaction, IBS pledged 250,000 shares, or 125,000 shares per contract (collectively, the "Pledged Shares") of Installed Building Products, Inc. common stock ("Common Stock"). The Pledged Shares secure its obligations under the contracts, and IBS retained dividend and voting rights in the Pledged Shares during the term of the pledge. The contracts obligate IBS to deliver to the buyer, on the applicable settlement date for each component referred to in footnote 10 below, up to one hundred percent (100%) of the number of Pledged Shares for such component or, at IBS' option, an equivalent amount of cash.

On August 12, 2025, IBS and the buyer entered into an amendment to the September 2023 forward sale contract and the May 2024 forward sale contract. On March 3, 2026, IBS and the buyer entered into a second amendment to the September 2023 forward sale contract (the "September Amendment Agreement") and the May 2024 forward sale contract (the "May Amendment Agreement" and collectively the "2026 Amendment Agreements"). The reference price for the 2026 Amendment Agreements was $314.06. The September Amendment Agreement amends certain terms of one of the forward sale contracts entered into in September 2023, covering 225,000 shares of Common Stock, including (i) extending the range of settlement dates for the components from March 9, 2026 through March 13, 2026 to the new settlement dates from May 24, 2027 through June 4, 2027,

(Continued from footnote 6) (ii) amending the Floor Price (as defined below) and the Cap Price (as defined below), and (iii) increasing the number of components from 5 to 9, with appropriate adjustment for the number of shares to be delivered on the respective settlement date for each component. The May Amendment Agreement amends certain terms of one of the forward sale contracts entered into in May 2024, covering 125,000 shares of Common Stock, including (i) extending the range of settlement dates for the components from March 9, 2026 through March 13, 2026 to the new settlement dates from May 24, 2027 through June 4, 2027, (ii) amending the Floor Price (as defined below) and the Cap Price (as defined below), and (iii) increasing the number of components from 5 to 9, with appropriate adjustments for the number of shares to be delivered on the respective settlement date for each component.

(Continued from footnote 7) The number of shares of Common Stock to be delivered to the buyer on the settlement date (or on which to base the amount of cash to be delivered to the buyer on such settlement date) under each Amendment Agreement is to be determined as follows: (a) if the VWAP of the Common Stock on the designated valuation date for the applicable component (each, a "Settlement Price") is less than or equal to $314.06 (the "Floor Price"), IBS will deliver to the buyer all of the Pledged Shares for the applicable component;

(Continued from footnote 8) (b) if such Settlement Price is greater than the Floor Price but less than or equal to $376.872 (the "Cap Price"), IBS will deliver to the buyer the number of shares equal to 100% of the Pledged Shares for the applicable component multiplied by a fraction, the numerator of which is the Floor Price and the denominator of which is such Settlement Price; and (c) if such Settlement Price is greater than the Cap Price, IBS will deliver to the buyer the number of shares equal to 100% of the Pledged Shares for the applicable component multiplied by a fraction, the numerator of which is the Floor Price plus the excess of such Settlement Price over the Cap Price, and the denominator of which is such Settlement Price.

Each component is exercisable on the same date as it expires, and the expiration dates for the components occur from May 24, 2027 through June 4, 2027 under the 2026 Amendment Agreements.

These securities are held directly by IBS. Mr. Edwards disclaims beneficial ownership in the reported securities except to the extent of his pecuniary interest therein.